UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                    -----------------------------------------

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of report (Date of earliest event reported): November 3, 2004
                                                         ----------------

                               CYTOGEN CORPORATION
      --------------------------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)

       Delaware                         000-14879               22-2322400
-----------------------------    ------------------------    -------------------
(State or Other Jurisdiction     (Commission File Number)     (I.R.S. Employer
     of Incorporation)                                       Identification No.)

    650 College Road East, CN 5308, Suite 3100, Princeton, NJ         08540
-------------------------------------------------------------      -------------
          (Address of Principal Executive Offices)                   (Zip Code)

       Registrant's telephone number, including area code: (609) 750-8200
                                                           --------------

--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)


     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_|  Written communications  pursuant to Rule 425 under the  Securities Act
(17 CFR 230.425)

     |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
Exchange Act (17 CFR 240.14d-2(b))

     |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
Exchange Act (17 CFR 240.13e-4(c))




ITEM 2.02       RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

     On November 3, 2004,  Cytogen  Corporation  announced its financial results
for the quarter ended  September 30, 2004, and  reaffirmed its recently  revised
2004 full year financial  guidance.  The full text of the November 3, 2004 press
release issued in connection  with the  announcement is attached as Exhibit 99.1
to this Current Report on Form 8-K.

     The information in this Form 8-K and the exhibit  attached hereto shall not
be deemed "filed" for purposes of Section 18 of the  Securities  Exchange Act of
1934 (the  "Exchange  Act") or  otherwise  subject  to the  liabilities  of that
section,  nor shall it be deemed  incorporated  by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

ITEM 9.01       FINANCIAL STATEMENTS AND EXHIBITS

(c)  Exhibits.

      Exhibit No.    Description
      -----------    -----------

         99.1        Press Release of Cytogen Corporation dated November 3, 2004





                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                CYTOGEN CORPORATION



                                                By: /s/ Michael D. Becker
                                                   -----------------------------
                                                   Michael D. Becker
                                                   President and Chief Executive
                                                   Officer

Dated:   November 3, 2004





                                  EXHIBIT INDEX


   Exhibit No.       Description
   -----------       -----------

      99.1           Press Release of Cytogen Corporation dated November 3, 2004